| Grant ID | DP150005 |
| Awarded On | May 20, 2015 |
| Title | Wireless neuromodulation treatment for bladder dysfunction secondary to cancer |
| Program | Product Development Research |
| Award Mechanism | New Company Product Development Award |
| Institution/Organization | Nexeon MedSystems, Inc |
| Principal Investigator/Program Director | Navid Khodaparast |
| Cancer Sites | Cervix Uteri, Prostate |
| Contracted Amount | $967,000 |
| Lay Summary |
Surgical resection and radiotherapy are used frequently in the treatment of prostate, cervical, and rectal cancers. While they can be life-saving therapies, these procedures often burden cancer survivors with secondary conditions such as overactive bladder (OAB). For some cancer patients and survivors, OAB symptoms are an understood outcome of life-saving cancer therapy, while others may view the risk of urinary dysfunction as a reason to forego or substitute potentially inferior forms of treatment. There is a pressing need for treating OAB in cancer patients and survivors; however, existing treatment protocols may not be suitable for patients developing symptoms secondary to cancer or treatm... |